Please provide your email address to receive an email when new articles are posted on . The proportion of men with overactive bladder increased significantly from 2015 to 2020. Results showed ...

In the United States, the prevalence of overactive bladder (OAB) among men was 14.5% in 2015 to 2020, reflecting a significant increase from 2005, according to a study published online July 15 in ...

"My bladder is ruining my life," Mr. X said as he sat down on the exam table, already nervous about his first time seeing a urologist. He had considered skipping his appointment, but he simply can't ...

Chinese investigators evaluated 15 years' worth of data from more than 18,000 adult men in the U.S. to better characterize OAB and its risk factors. The overall presence of OAB increased significantly ...

In a recent study published in the journal Scientific Reports, researchers in China examined the trends and prevalence of overactive bladder (OAB) among adult men in the United States of America (US) ...

A study of NHANES 2005-2020 data found that the prevalence of overactive bladder among men in the US increased significantly from 11.7% in 2009-2014 to 14.5% in 2015-2020. Overactive bladder (OAB) ...

The medication vibegron led to improvements in symptoms of overactive bladder and overall quality of life in men undergoing treatment for benign prostatic hyperplasia, according to findings from a ...

OAB is commonly treated with a class of medicines called anticholinergics or antimuscarinics. These medicines block chemicals in your body that help the bladder to squeeze. By blocking these chemicals ...

Overactive bladder (OAB) causes a person to urinate more frequently and to feel a sudden and intense need to urinate. Urge incontinence occurs when this urge to urinate causes leaking. Although the ...

DEAR DR. ROACH: I’m a 87-year-old male who was diagnosed with an overactive bladder. I’ve tried several over-the-counter medications, and my general physician proscribed tolterodine. Nothing has ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) symptoms receiving pharmacologic therapy for benign prostatic ...

Credit: Shutterstock. Vibegron is an oral, small molecule beta-3 adrenergic receptor agonist. A phase 3 study evaluating the efficacy and safety of vibegron in men with overactive bladder (OAB) ...